Tuan Huy Tran, MD
Endocrinology, Diabetes & Metabolism · Metairie, LANPI 1750369161
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $20,475 of the $34,015 with a category attached, or 60.2%. 53 manufacturers reported payments, led by Bayer at 30.6% of the total. Reporting peaked in 2022 at $10,533 and has fallen 70.4% since, to $3,122 in 2025.
Across 1,096 payments — averaging $31.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$10K
- Corcept Therapeutics$5K
- Novo Nordisk$3K
- Novartis$2K
- Lilly USA, LLC$2K
- Dexcom, Inc.$1K
- plus $11K from 47 others
Across 369 payments — averaging $5264.09 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$801K
- Bayer$592K
- CSL Behring$187K
- AstraZeneca$157K
- AbbVie$114K
- GSK$43K
- plus $48K from 5 others
What the payments were for
- Consulting fees$2,2507%
- Speaking & faculty fees$7,86623%
- Travel & lodging$3,37710%
- Food & beverage$20,47560%
- Education$470%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Kerendia$8,745
- Korlym$3,689
- iLet Bionic Pancreas$1,053
- LEQVIO$952
- DEXCOM G6 TRANSMITTER$247
- FreeStyle Libre 2$154
- FREESTYLE LIBRE 3$133
- GORE ENFORM Biomaterial$130
- Ozempic$125
- FARXIGA$119
- DEXCOM CGM$112
How this compares
$34,015 in reported general payments places this provider in the 85th percentile of 95 endocrinology, diabetes & metabolism providers in Louisiana.
See all endocrinology, diabetes & metabolism providers in Louisiana →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 505 | $650,383 |
| MounjaroTirzepatide | 412 | $536,130 |
| KorlymMifepristone | 12 | $484,079 |
| JardianceEmpagliflozin | 369 | $368,961 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 184 | $194,669 |
| FarxigaDapagliflozin Propanediol | 185 | $181,030 |
| KerendiaFinerenone | 142 | $143,680 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 99 | $116,157 |
| TrulicityDulaglutide | 76 | $101,856 |
| JanuviaSitagliptin Phosphate | 111 | $100,457 |
| Tresiba Flextouch U-100Insulin Degludec | 131 | $99,172 |
| ForteoTeriparatide | 21 | $97,659 |
| Tresiba Flextouch U-200Insulin Degludec | 58 | $80,218 |
| RybelsusSemaglutide | 55 | $77,141 |
| Novolog FlexpenInsulin Aspart | 180 | $47,989 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $2,664 | $744,986627 claims |
| Lilly USA, LLCMounjaro, Trulicity, Forteo, Humalog | $1,705 | $743,152533 claims |
| Corcept TherapeuticsKorlym | $4,560 | $484,07912 claims |
| Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr | $337 | $416,807414 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $913 | $205,281254 claims |
| AstraZenecaFarxiga | $1,237 | $181,030185 claims |
| MerckJanuvia, Janumet, Janumet Xr | $880 | $174,008194 claims |
| BayerKerendia | $10,410 | $143,680142 claims |
| AbbVieSynthroid | $604 | $23,692277 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $501 | $8,7201,096 claims |
| Arbor Pharmaceuticals, Inc.Edarbi | $17 | $6,81327 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 95 endocrinology, diabetes & metabolism providers in Louisiana.
Other endocrinology, diabetes & metabolism in Metairie
- Julie TalaveraMetairie$49K
- Jonathan WiseMetairie$20K
- Joseph MurrayMetairie$7K
- Miguel RiveraMetairie$7K
- Escipion PedrozaMetairie$2K
- Timothy GilbertBaton Rouge$985K
- Vivian FonsecaNew Orleans$658K
- Abdul KhanHammond$587K
- Marideli ScanlanMarrero$444K
- Justin FontenotLafayette$397K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.